P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Published:2016-01 Issue: Volume:3 Page:54-66
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Katayama Ryohei^ORCID,Sakashita Takuya,Yanagitani Noriko,Ninomiya Hironori,Horiike Atsushi,Friboulet Luc^ORCID,Gainor Justin F.,Motoi Noriko,Dobashi Akito,Sakata Seiji,Tambo Yuichi,Kitazono Satoru,Sato Shigeo,Koike Sumie,John Iafrate A.,Mino-Kenudson Mari,Ishikawa Yuichi,Shaw Alice T.,Engelman Jeffrey A.,Takeuchi Kengo,Nishio Makoto,Fujita Naoya

Funder

MEXT/JSPS KAKENHI

MHLW/AMED

Princess Takamatsu Cancer Research Fund

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference44 articles.

1. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance;Branford;Blood,2002

2. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties;Chiba;Hepatology,2006

3. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar;Chuan Tang;Int. J. Cancer,2014